Aurobindo Pharma Ltd, the Rs 1,472-crore pharma major, is upbeat on the European markets, following its two key acquisitions in 2006. With the UK-based Milpharm Ltd and the Netherlands-based Pharmacin International in its fold, the company expects to substantially boost its revenues in the fiscal 2007-08.

The Hyderabad-based Aurobindo Pharma, with strengths in generic pharmaceuticals and active pharmaceutical ingredients (APIs), hopes to gain on two counts through these acquisitions. First, it would quickly achieve a large portfolio of products with regulatory approvals in Europe. Secondly, it would gain new markets and reach them faster.

Contd on page 2......